Low-dose subcutaneous immunotherapy for pediatric house dust mite allergy

Abstract Background Pediatric allergic rhinitis (AR) caused by house dust mite (HDM) is common and may be treated with subcutaneous allergen immunotherapy (SCIT). However, the optimal maintenance dose in children remains unclear. Methods We conducted a cross-sectional comparative study among pediatric patients treated with low-dose (50 AU) versus standard-dose (500 AU) HDM SCIT. The Total Nasal Symptom Score (TNSS) and Total Medication Score (TMS) were assessed. Results Among 71 patients, 32 received low-dose and 39 received standard-dose SCIT. The two groups had comparable TNSS and TMS (TNSS: 5.59 vs. 5.35; TMS: 1.68 vs. 1.23, respectively). Conclusion Low-dose HDM SCIT may provide symptom control comparable to standard-dose SCIT in children, with potential for fewer systemic reactions.